Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)

Although phase 2 data suggested baricitinib as a potential treatment for patients
with SLE, which was supported in SLE-BRAVE-I, this result was not replicated in SLE-BRAVE-II.
No new safety signals were observed.

Related Keywords

,American College Of Rheumatology ,Rev Rheumatol ,Res Ther ,Englj Med ,Rheum Dis ,Database Syst Rev ,Biol Med ,Rev Drug Discov ,Sci Med ,American College ,Rev Clin Immunol ,